Newsletter | May 31, 2023

05.31.23 -- How Research And Development Is Influencing The Future Of Clinical Trials

Reimagining The Future: One Chapter At A Time

Charles Dickens’ famous opening line from his 1859 novel A Tale of Two Cities, “It was the best of times, it was the worst of times,” is a fitting description of the pharmaceutical space in recent years. Get a glimpse of how the industry has emerged from the tumultuous episode of the COVID-19 pandemic, stronger and emboldened.

Pharma R&D Annual Review 2023

The story of pharma R&D is an epic tale, so a literary theme for this year’s report was quite fitting. Although the COVID-19 chapter has not quite finished its final act, it appears the industry is emerging from this boisterous period recovered and enlivened. Find out if the 2023 pipeline was a page-turner.

New Active Substances Launched In 2022: A 2023 R&D Supplement

This report looks at the industry’s success stories of 2022 — the drugs that were launched onto the market for the first time. It focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use.

Citeline’s Pharmaprojects & Biomedtracker Solution

Together, Pharmaprojects and Biomedtracker form the leading end-to-end intelligence solution designed to help understand the global drug development pipeline and competitive landscape, from pre-clinical to market. Real-time tracking and analysis enable sponsors to make better-informed decisions faster.

Request Information
Pharmaprojects By Citeline

With Pharmaprojects, leverage your mastery of the R&D space to create winning strategies, identify the right drugs to license, and support the key decisions that will drive your company forward.

Request Information